Compare · HRMY vs LLY
HRMY vs LLY
Side-by-side comparison of Harmony Biosciences Holdings Inc. (HRMY) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HRMY and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.04T, about 569.0x HRMY ($1.83B).
- Over the past year, HRMY is down 10.5% and LLY is up 44.9% - LLY leads by 55.4 points.
- LLY has been more active in the news (21 items in the past 4 weeks vs 12 for HRMY).
- LLY has more recent analyst coverage (25 ratings vs 23 for HRMY).
- Company
- Harmony Biosciences Holdings Inc.
- Eli Lilly and Company
- Price
- $31.82+0.66%
- $1082.08-2.07%
- Market cap
- $1.83B
- $1.04T
- 1M return
- +1.74%
- +15.75%
- 1Y return
- -10.48%
- +44.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 21
- Recent ratings
- 23
- 25
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest HRMY
- Harmony Biosciences to Participate in Upcoming Investor Conferences
- SEC Form 4 filed by Director Germano Geno J
- SEC Form 3 filed by new insider Germano Geno J
- SEC Form 4 filed by Director Szyper Linda M
- SEC Form 4 filed by Director Philip Ron M
- SEC Form 4 filed by Director Graf R. Mark
- SEC Form 4 filed by Director Sabater Juan A.
- SEC Form 4 filed by Director Sender Gary
- CHIEF MEDICAL OFFICER Budur Kumar converted options into 18,750 shares and covered exercise/tax liability with 8,882 shares, increasing direct ownership by 69% to 24,115 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by CHIEF FINANCIAL OFFICER Reicin Glenn
Latest LLY
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
- SEC Form 8-K filed by Eli Lilly and Company
- Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,987 units (SEC Form 4)